The National Institutes of Health (NIH) defines a Clinical Trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions. Clinical trials help develop novel drugs (Investigational Products) by providing early access to patients who volunteer to participate in the research study.
Carolina BioOncology Institute and our expert Providers participate in the national clinical trials listed below. The eligibility criteria enables patients with advanced solid tumors to access these Investigational Products. Over the past 15 years, our Clinic has opened over 100 Oncology clinical trials and our experienced staff are happy to discuss options for determining trial eligibility Please view the list of trials below that are currently enrolling patients:
AbbVie M21-404
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors.
AbbVie M21-410
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab.
AbbVie M24-122
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
AbbVie M24-742
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
AbbVie M24-893
A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-291 in Non-Hodgkin’s Lymphoma
ClinicalTrials.gov link still pending
Acrivon ACR-2316-101
Phase 1 study of ACR-2316 in subjects with advanced solid tumors
ClinicalTrials.gov link still pending
Apollo AP10CP01
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Aptevo Therapeutics ALG.APV-527-101
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
Astellas 1012-CL-0101
A Study of ASP1012 in Adults With Solid Tumors
Aulos CP-AU-007-01
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
BioNTech BNT314-01
Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors
Bright Peak Therapeutics BPT567-101
Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients with Advanced Solid Tumors (SUMMIT-1)
Corbus CRB-701-01
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
CUE Biopharma CUE-102-01
A Phase I Study in Patients with HLA-A*0201 + and WT1 + Recurrent/Metastatic Cancers.
CytoMx CTMX-2051-01
First In Human Study of CX-2051 in Advanced Solid Tumors
Duality Bio DB-1419-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors
EMD Serono MS202650-0001
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination with Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer
ClinicalTrials.gov link still pending
Exelixis XB010-101
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov link still pending
Exelixis XL495-101
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
GI Innovation GII-101-P101
GI-101 as Single Agent or in Combination with Pembrolizumab, Levantinib or Local Radiotherapy in Advanced Solid Tumors.
IconOVir ICVB-1042-CLN01
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors.
Macrogenics CP-MGC018-02
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination with MGD019 in Participants with Advanced Solid Tumors.
Clinicaltrials.gov link still pending
MBrace MBRC-101-001
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors
Multitude Therapeutics AMT-116-01
AMT-116 in Patients With Advanced Solid Tumors
Nuvation NUV-1511-01
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
PEEL Therapeutics PEEL-224-001
An Early Phase Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors.
Phanes PT199X1101
A Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination with a PD-1 Inhibitor.
Qurgen SON-DP-A001-ST
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Revolution Medicines RMC-9805-01
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumor
Sairopa SRP-22C102
An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tumors.
Teva TV56278-ONC-10203
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors
Trethera TRE515-T-02
A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study with Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects with Solid Tumors.
Wugen WUN-101-02
A Phase 1/b Study of WU-NK-101 in Combination with Cetuximab for Advanced and/or Metastatic Colorectal Cancer (CRC) and Advanced and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
